Role of innate immunity and fibrinolysis in the development of post thrombotic syndrome: a case-control study

Role of innate immunity and fibrinolysis in the development of post thrombotic syndrome: a case-control study - Immunity and fibrinolysis in PTS / If PTS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35458

Enrollment

Registered

2011-11-04

Start date

2012-01-09

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post phlebitic syndrome

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All adult and consenting.;Cases: - Having had a DVT 2-10 years ago - PTS according to the Villalta scale: Villalta score >=5 on two or more consecutive visits that were at least 3 months apart or venous ulceration;Controls: - Having had a DVT 2-10 years ago - No PTS;Healthy controls: - Never had a DVT during their life - No venous insufficiency caused by other factors (CEAP

Exclusion criteria

Exclusion criteria: - Preexistent venous insufficiency (skin signs C3-C6 on CEAP score or requiring ECS therapy)

Design outcomes

Primary

Measure	Time frame
The primary outcome will be the difference in levels of plasma concentrations of markers in relation to the outcome PTS between participants with PTS and participants without PTS	—

Secondary

Measure	Time frame
- Dose-dependent relation between the level of markers and severity of PTS. - Plasma concentration of markers in healthy controls that never had a DVT, compared to patients that have had a DVT.	—

Countries

Netherlands

Outcome results